Regeneron, CytomX ink potentially $2B bispecific immunotherapy dealBusiness, TherapeuticsThe companies hope pairing the capabilities of the two platforms will allow for the development of conditionally-activated investigational bispecific cancer therapies. Read more November 17, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/04/BioSpaceRegeneron.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-11-17 11:20:362022-11-17 11:20:36Regeneron, CytomX ink potentially $2B bispecific immunotherapy deal
